Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.
Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Cell Rep. 2019 Oct 1;29(1):104-117.e4. doi: 10.1016/j.celrep.2019.08.088.
The glucocorticoid receptor (GR) acts as a ubiquitous cortisol-dependent transcription factor (TF). To identify co-factors, we used protein-fragment complementation assays and found that GR recognizes FLI1 and additional ETS family proteins, TFs relaying proliferation and/or migration signals. Following steroid-dependent translocation of FLI1 and GR to the nucleus, the FLI1-specific domain (FLS) binds with GR and strongly enhances GR's transcriptional activity. This interaction has functional consequences in Ewing sarcoma (ES), childhood and adolescence bone malignancies driven by fusions between EWSR1 and FLI1. In vitro, GR knockdown inhibited the migration and proliferation of ES cells, and in animal models, antagonizing GR (or lowering cortisol) retarded both tumor growth and metastasis from bone to lung. Taken together, our findings offer mechanistic rationale for repurposing GR-targeting drugs for the treatment of patients with ES.
糖皮质激素受体 (GR) 作为一种普遍存在的依赖于皮质醇的转录因子 (TF) 发挥作用。为了鉴定共因子,我们使用蛋白质片段互补测定法发现,GR 识别 FLI1 和其他 ETS 家族蛋白,这些蛋白传递增殖和/或迁移信号。在类固醇依赖性的 FLI1 和 GR 向核内易位后,FLI1 特异性结构域 (FLS) 与 GR 结合并强烈增强 GR 的转录活性。这种相互作用在由 EWSR1 和 FLI1 融合驱动的儿童和青少年骨骼恶性肿瘤尤文肉瘤 (ES) 中具有功能后果。在体外,GR 敲低抑制 ES 细胞的迁移和增殖,在动物模型中,拮抗 GR(或降低皮质醇)既延迟了肿瘤生长,也延迟了从骨到肺的转移。总之,我们的研究结果为重新利用靶向 GR 的药物治疗 ES 患者提供了机制依据。